他汀类药物对肺栓塞严重程度的影响——回顾性数据分析

IF 3.4 3区医学 Q2 HEMATOLOGY

Research and Practice in Thrombosis and Haemostasis Pub Date : 2025-07-01 DOI:10.1016/j.rpth.2025.102982

Paul Gressenberger , Bettina Wachmann , Andrea Borenich , Gudrun Pregartner , Lisa Moser , Nikolaus Schreiber , Johannes Schmid , Ewald Kolesnik , Günther Silbernagel , Reinhard B. Raggam , Marianne Brodmann , Thomas Gary

{"title":"他汀类药物对肺栓塞严重程度的影响——回顾性数据分析","authors":"Paul Gressenberger , Bettina Wachmann , Andrea Borenich , Gudrun Pregartner , Lisa Moser , Nikolaus Schreiber , Johannes Schmid , Ewald Kolesnik , Günther Silbernagel , Reinhard B. Raggam , Marianne Brodmann , Thomas Gary","doi":"10.1016/j.rpth.2025.102982","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Recent studies have demonstrated decreased rates of venous thrombotic events, including pulmonary embolism (PE), in patients taking statins. It, however, remains elusive whether statins could also impact PE severity.</div></div><div><h3>Objectives</h3><div>To investigate a potential association between statin use and the severity of PE in a retrospective cohort.</div></div><div><h3>Methods</h3><div>We performed a retrospective data analysis of patients with PE confirmed by computed tomography pulmonary angiography between January 1, 2010, and December 31, 2019, at the University Hospital Graz, Austria. PE severity was assessed based on the 2019 European Society of Cardiology guidelines.</div></div><div><h3>Results</h3><div>Of 1590 patients analyzed, 235 (14.7%) were statin users. Statin users were significantly older than nonusers (median, 74 years [IQR, 66-80] vs 67 years [IQR, 52-78]; <em>P</em> < .001) and had a higher body mass index (BMI kg/m<sup>2</sup>; median, 27.4 [IQR, 24.7-30.7] vs 26.2 [IQR, 23.6-29.7]; <em>P</em> = .001). Statin users had a significantly higher prevalence of comorbidities, including kidney insufficiency, arterial hypertension, diabetes, hyperlipidemia, atherosclerotic cardiovascular disease (all <em>P</em> < .001), and heart failure (<em>P</em> = .006), while the nonstatin group had a higher prevalence of cancer (29.6% vs 14.0%; <em>P</em> = .04). Our study revealed a significantly smaller proportion of low-risk PE in statin users compared with nonstatin users (12.3% vs 19.9%; <em>P</em> = .006). After matching the groups based on sex (male and female), age, and BMI (kg/m<sup>2</sup>), no significant differences in PE severity were found.</div></div><div><h3>Conclusion</h3><div>Statin use was not associated with PE severity. The smaller proportion of low-risk PE in statin users is likely attributable to their older age, higher BMI, and comorbidities.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 5","pages":"Article 102982"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The impact of statins on pulmonary embolism severity—a retrospective data analysis\",\"authors\":\"Paul Gressenberger , Bettina Wachmann , Andrea Borenich , Gudrun Pregartner , Lisa Moser , Nikolaus Schreiber , Johannes Schmid , Ewald Kolesnik , Günther Silbernagel , Reinhard B. Raggam , Marianne Brodmann , Thomas Gary\",\"doi\":\"10.1016/j.rpth.2025.102982\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Recent studies have demonstrated decreased rates of venous thrombotic events, including pulmonary embolism (PE), in patients taking statins. It, however, remains elusive whether statins could also impact PE severity.</div></div><div><h3>Objectives</h3><div>To investigate a potential association between statin use and the severity of PE in a retrospective cohort.</div></div><div><h3>Methods</h3><div>We performed a retrospective data analysis of patients with PE confirmed by computed tomography pulmonary angiography between January 1, 2010, and December 31, 2019, at the University Hospital Graz, Austria. PE severity was assessed based on the 2019 European Society of Cardiology guidelines.</div></div><div><h3>Results</h3><div>Of 1590 patients analyzed, 235 (14.7%) were statin users. Statin users were significantly older than nonusers (median, 74 years [IQR, 66-80] vs 67 years [IQR, 52-78]; <em>P</em> < .001) and had a higher body mass index (BMI kg/m<sup>2</sup>; median, 27.4 [IQR, 24.7-30.7] vs 26.2 [IQR, 23.6-29.7]; <em>P</em> = .001). Statin users had a significantly higher prevalence of comorbidities, including kidney insufficiency, arterial hypertension, diabetes, hyperlipidemia, atherosclerotic cardiovascular disease (all <em>P</em> < .001), and heart failure (<em>P</em> = .006), while the nonstatin group had a higher prevalence of cancer (29.6% vs 14.0%; <em>P</em> = .04). Our study revealed a significantly smaller proportion of low-risk PE in statin users compared with nonstatin users (12.3% vs 19.9%; <em>P</em> = .006). After matching the groups based on sex (male and female), age, and BMI (kg/m<sup>2</sup>), no significant differences in PE severity were found.</div></div><div><h3>Conclusion</h3><div>Statin use was not associated with PE severity. The smaller proportion of low-risk PE in statin users is likely attributable to their older age, higher BMI, and comorbidities.</div></div>\",\"PeriodicalId\":20893,\"journal\":{\"name\":\"Research and Practice in Thrombosis and Haemostasis\",\"volume\":\"9 5\",\"pages\":\"Article 102982\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Research and Practice in Thrombosis and Haemostasis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2475037925003061\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Practice in Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2475037925003061","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

最近的研究表明，服用他汀类药物的患者静脉血栓形成事件（包括肺栓塞（PE））的发生率降低。然而，他汀类药物是否也会影响PE的严重程度仍然难以捉摸。目的通过回顾性队列研究他汀类药物使用与PE严重程度之间的潜在关联。方法：我们对2010年1月1日至2019年12月31日在奥地利格拉茨大学医院通过计算机断层扫描肺血管造影确诊的PE患者进行回顾性数据分析。PE严重程度是根据2019年欧洲心脏病学会指南进行评估的。结果1590例患者中，235例（14.7%）为他汀类药物使用者。他汀类药物服用者明显大于非服用者(中位数为74岁[IQR， 66-80] vs 67岁[IQR， 52-78]；P & lt;.001)，体重指数(BMI kg/m2；中位数，27.4 [IQR, 24.7-30.7] vs 26.2 [IQR, 23.6-29.7]；P = .001)。他汀类药物使用者的合并症患病率明显更高，包括肾功能不全、动脉高血压、糖尿病、高脂血症、动脉粥样硬化性心血管疾病(所有P <；.001)和心力衰竭（P = .006），而非他汀类药物组的癌症患病率更高(29.6% vs 14.0%；P = .04)。我们的研究显示，与非他汀类药物使用者相比，他汀类药物使用者中低风险PE的比例明显更小(12.3% vs 19.9%；P = .006)。根据性别（男性和女性）、年龄和BMI （kg/m2）对各组进行匹配后，未发现PE严重程度有显著差异。结论他汀类药物的使用与PE严重程度无关。他汀类药物使用者中低风险PE的比例较小可能归因于他们的年龄较大、BMI较高和合并症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The impact of statins on pulmonary embolism severity—a retrospective data analysis

Background

Recent studies have demonstrated decreased rates of venous thrombotic events, including pulmonary embolism (PE), in patients taking statins. It, however, remains elusive whether statins could also impact PE severity.

Objectives

To investigate a potential association between statin use and the severity of PE in a retrospective cohort.

Methods

We performed a retrospective data analysis of patients with PE confirmed by computed tomography pulmonary angiography between January 1, 2010, and December 31, 2019, at the University Hospital Graz, Austria. PE severity was assessed based on the 2019 European Society of Cardiology guidelines.

Results

Of 1590 patients analyzed, 235 (14.7%) were statin users. Statin users were significantly older than nonusers (median, 74 years [IQR, 66-80] vs 67 years [IQR, 52-78]; P < .001) and had a higher body mass index (BMI kg/m²; median, 27.4 [IQR, 24.7-30.7] vs 26.2 [IQR, 23.6-29.7]; P = .001). Statin users had a significantly higher prevalence of comorbidities, including kidney insufficiency, arterial hypertension, diabetes, hyperlipidemia, atherosclerotic cardiovascular disease (all P < .001), and heart failure (P = .006), while the nonstatin group had a higher prevalence of cancer (29.6% vs 14.0%; P = .04). Our study revealed a significantly smaller proportion of low-risk PE in statin users compared with nonstatin users (12.3% vs 19.9%; P = .006). After matching the groups based on sex (male and female), age, and BMI (kg/m²), no significant differences in PE severity were found.

Conclusion

Statin use was not associated with PE severity. The smaller proportion of low-risk PE in statin users is likely attributable to their older age, higher BMI, and comorbidities.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊